<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22437938</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>07</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1474-1741</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Mar</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Immunology</Title>
          <ISOAbbreviation>Nat Rev Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Coordinated regulation of myeloid cells by tumours.</ArticleTitle>
        <Pagination>
          <StartPage>253</StartPage>
          <EndPage>268</EndPage>
          <MedlinePgn>253-68</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/nri3175</ELocationID>
        <Abstract>
          <AbstractText>Myeloid cells are the most abundant nucleated haematopoietic cells in the human body and are a collection of distinct cell populations with many diverse functions. The three groups of terminally differentiated myeloid cells - macrophages, dendritic cells and granulocytes - are essential for the normal function of both the innate and adaptive immune systems. Mounting evidence indicates that the tumour microenvironment alters myeloid cells and can convert them into potent immunosuppressive cells. Here, we consider myeloid cells as an intricately connected, complex, single system and we focus on how tumours manipulate the myeloid system to evade the host immune response.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gabrilovich</LastName>
            <ForeName>Dmitry I</ForeName>
            <Initials>DI</Initials>
            <AffiliationInfo>
              <Affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33647, USA. dmitry.gabrilovich@ moffitt.org</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ostrand-Rosenberg</LastName>
            <ForeName>Suzanne</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bronte</LastName>
            <ForeName>Vincenzo</ForeName>
            <Initials>V</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA084488</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA100062</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA141438</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>03</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nat Rev Immunol</MedlineTA>
        <NlmUniqueID>101124169</NlmUniqueID>
        <ISSNLinking>1474-1733</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22437938</ArticleId>
        <ArticleId IdType="mid">NIHMS442658</ArticleId>
        <ArticleId IdType="pmc">PMC3587148</ArticleId>
        <ArticleId IdType="doi">10.1038/nri3175</ArticleId>
        <ArticleId IdType="pii">nri3175</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4994190</ArticleId>
            <ArticleId IdType="pubmed">20371344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20856220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coussens LM, Pollard JW. Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol. 2011;3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3039933</ArticleId>
            <ArticleId IdType="pubmed">21123394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khazaie K, et al.  The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011;30:45–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21287360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev. 2010;234:45–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20193011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogg DK, et al.  A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science. 2006;311:83–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16322423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onai N, et al.  Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol. 2007;8:1207–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17922016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naik SH, et al.  Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol. 2007;8:1217–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17922015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev. 234:18–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20193009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Idoyaga J, Steinman RM. SnapShot: Dendritic Cells. Cell. 2011;146:660–660. e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21854989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234:142–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3507434</ArticleId>
            <ArticleId IdType="pubmed">20193017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev. 2010;234:18–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20193009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dominguez PM, Ardavin C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol Rev. 2010;234:90–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20193014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941–952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15573129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinzon-Charry A, et al.  Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer. 2007;97:1251–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2360464</ArticleId>
            <ArticleId IdType="pubmed">17923873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perrot I, et al.  Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol. 2007;178:2763–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17312119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellone G, et al.  Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol. 2006;177:3448–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16920987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee BN, et al.  Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions. Cancer. 2006;107:999–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16874820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ormandy LA, et al.  Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol. 2006;12:3275–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4087975</ArticleId>
            <ArticleId IdType="pubmed">16718852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: A mechanism for immunosuppression. Immunol Cell Biol. 2005;83:451–461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16174093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancino A, et al.  Divergent effects of hypoxia on dendritic cell functions. Blood. 2008;112:3723–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18694997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elia AR, et al.  Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. J Leukoc Biol. 2008;84:1472–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18725395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M, et al.  HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol Cell Biol. 2010;88:165–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19841638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novitskiy SV, et al.  Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112:1822–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2518889</ArticleId>
            <ArticleId IdType="pubmed">18559975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gottfried E, et al.  Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107:2013–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16278308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herber DL, et al.  Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010;16:880–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917488</ArticleId>
            <ArticleId IdType="pubmed">20622859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghiringhelli F, et al.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med. 2005;202:919–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213166</ArticleId>
            <ArticleId IdType="pubmed">16186184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin A, Schildknecht A, Nguyen LT, Ohashi PS. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett. 2010;127:77–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19778555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norian LA, et al.  Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 2009;69:3086–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2848068</ArticleId>
            <ArticleId IdType="pubmed">19293186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watkins SK, et al.  FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest. 2011;121:1361–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3069771</ArticleId>
            <ArticleId IdType="pubmed">21436588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dumitriu IE, Dunbar DR, Howie SE, Sethi T, Gregory CD. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol. 2009;182:2795–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19234174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, et al.  Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol. 2009;182:6207–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19414774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JR, et al.  Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest. 2003;83:1457–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14563947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munn DH, et al.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC449750</ArticleId>
            <ArticleId IdType="pubmed">15254595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baban B, et al.  IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol. 2009;183:2475–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677163</ArticleId>
            <ArticleId IdType="pubmed">19635913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2724991</ArticleId>
            <ArticleId IdType="pubmed">19029990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12401408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70:325–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19236898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20144856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current opinion in immunology. 2010;22:231–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20144856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steidl C, et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875–85. This study identified a gene signature of TAMs that was associated with primary treatment failure of Hodgkin's lymphoma patients, and demonstrated that the level of macrophages in Hodgkin's lymphoma patients is prognostic of clinical outcome.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2897174</ArticleId>
            <ArticleId IdType="pubmed">20220182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin EY, et al.  Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer research. 2006;66:11238–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17114237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian B, et al.  A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One. 2009;4:e6562. This study demonstrated that macrophages play a critical role in metastatic cell seeding and in progression of metastatic disease.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2721818</ArticleId>
            <ArticleId IdType="pubmed">19668347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, et al.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114:3625–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2766678</ArticleId>
            <ArticleId IdType="pubmed">19710503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20510870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNardo DG, et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91–102. This study demonstrated that in transgenic mice with mammary carcinoma TAMS achieve a pro-tumor and pro-metastatic phenotype in response to CD4+ T cell-produced IL-4. These findings demonstrate that the adaptive immune system significantly drives the pro-tumor activity of the innate immune system.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2778576</ArticleId>
            <ArticleId IdType="pubmed">19647220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murai M, et al.  Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009;10:1178–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2898179</ArticleId>
            <ArticleId IdType="pubmed">19783988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curiel TJ, et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15322536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torroella-Kouri M, et al.  Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 2009;69:4800–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19458073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuang DM, et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327–37. This study demonstrated that CD68+ monocytes in peritumoral stroma of hepatocellular carcinoma patients express PD-L1 (B7-H1/CD274), induce T cell anergy, promote tumor progression, and are associated with poor survival.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2715058</ArticleId>
            <ArticleId IdType="pubmed">19451266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez PC, et al.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15313928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian BZ, et al.  CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222–225. Using a transgenic mouse mammary carcinoma system, this study demonstrated that tumor- and stromal cell-produced CCL2 recruits inflammatory monocytes and metastasis-associated macrophages that promote metastasis, and that blocking CCL2-CCR2 signaling blocks the recruitment of inflammatory monocytes, prolongs survival, and inhibits metastasis.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3208506</ArticleId>
            <ArticleId IdType="pubmed">21654748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Connell PA, Surette AP, Liwski RS, Svenningsson P, Waisman DM. S100A10 regulates plasminogen-dependent macrophage invasion. Blood. 2010;116:1136–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20424186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phipps K, Surette A, O'Connell P, Weaisman D. Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Research. 2011 in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22042827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movahedi K, et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70:5728–39. This study demonstrated that distinct subpopulations of TAMs can be idnetified based on their constellation of M1 and M2-like markers and that the different subpopulations localize to different regions of solid tumors where they have distinct functions.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20570887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pucci F, et al.  A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood. 2009;114:901–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19383967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol. 2010;184:702–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3226722</ArticleId>
            <ArticleId IdType="pubmed">20018620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiemessen MM, et al.  CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A. 2007;104:19446–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2148309</ArticleId>
            <ArticleId IdType="pubmed">18042719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song L, et al.  Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest. 2009;119:1524–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2689106</ArticleId>
            <ArticleId IdType="pubmed">19411762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15894262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong SC, et al.  Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol. 2010;40:2296–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20468007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreu P, et al.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 2010;17:121–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3082507</ArticleId>
            <ArticleId IdType="pubmed">20138013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagemann T, et al.  Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16585599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Summers C, et al.  Neutrophil kinetics in health and disease. Trends Immunol. 2010;31:318–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2930213</ArticleId>
            <ArticleId IdType="pubmed">20620114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006;24:1997–2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16648500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen HK, et al.  Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009;27:4709–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19720929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilie M, et al.  Predictive clinical outcome of the intratumoral CD66b-positive neutrophil- to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21953630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YW, et al.  Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol. 2011;54:497–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21112656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15542429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450:825–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18064003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowanetz M, et al.  Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A. 2010;107:21248–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3003076</ArticleId>
            <ArticleId IdType="pubmed">21081700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103:12493–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1531646</ArticleId>
            <ArticleId IdType="pubmed">16891410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houghton AM, et al.  Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16:219–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2821801</ArticleId>
            <ArticleId IdType="pubmed">20081861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Granot Z, et al.  Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20:300–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3172582</ArticleId>
            <ArticleId IdType="pubmed">21907922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridlender ZG, et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16:183–94. Neutrophil granulocytes are demonstrated to undergo a shift among different transitional activation stages, which is regulated by TGFβ.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2754404</ArticleId>
            <ArticleId IdType="pubmed">19732719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Santo C, et al.  Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol. 2010;11:1039–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3001335</ArticleId>
            <ArticleId IdType="pubmed">20890286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davey MS, et al.  Failure to detect production of IL-10 by activated human neutrophils. Nat Immunol. 2011;12:1017–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22012430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, et al.  The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:425. author reply 426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1941787</ArticleId>
            <ArticleId IdType="pubmed">17210725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peranzoni E, et al.  Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22:238–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20171075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11:802–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3478130</ArticleId>
            <ArticleId IdType="pubmed">21237299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolcetti L, et al.  Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40:22–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19941314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181:5791–802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2575748</ArticleId>
            <ArticleId IdType="pubmed">18832739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movahedi K, et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18272812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandruzzato S, et al.  IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19414811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haile LA, Gamrekelashvili J, Manns MP, Korangy F, Greten TF. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol. 2010;185:203–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20525890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Ginderachter JA, et al.  Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood. 2006;108:525–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16527895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, et al.  Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood. 2000;96:3838–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2734459</ArticleId>
            <ArticleId IdType="pubmed">11090068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1857267</ArticleId>
            <ArticleId IdType="pubmed">17476345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev S, et al.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:8270–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19088044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Montero CM, et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3401888</ArticleId>
            <ArticleId IdType="pubmed">18446337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solito S, et al.  A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011 A relationship between human MDSCs and immature promyelocyte is shown in this manuscript; more importantly, blood levels of these cells are inversely correlated with the response to chemotherapy in breast and colon cancer patients.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3709641</ArticleId>
            <ArticleId IdType="pubmed">21734236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corzo CA, et al.  Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182:5693–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2833019</ArticleId>
            <ArticleId IdType="pubmed">19380816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raychaudhuri B, et al.  Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011;13:591–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3107102</ArticleId>
            <ArticleId IdType="pubmed">21636707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez PC, et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2900845</ArticleId>
            <ArticleId IdType="pubmed">19201693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vuk-Pavlovic S, et al.  Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate. 2010;70:443–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2935631</ArticleId>
            <ArticleId IdType="pubmed">19902470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoechst B, et al.  A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135:234–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18485901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filipazzi P, et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17577033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serafini P, et al.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203:2691–702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118163</ArticleId>
            <ArticleId IdType="pubmed">17101732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn J-I, Collazo M, Shalova I, Biswas S, Gabrilovich D. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012 in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3250305</ArticleId>
            <ArticleId IdType="pubmed">21954284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandau S, et al.  Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol. 2011;89:311–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21106641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu T, et al.  Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest. 2011;121:4015–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195459</ArticleId>
            <ArticleId IdType="pubmed">21911941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16056256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2135607</ArticleId>
            <ArticleId IdType="pubmed">17603493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molon B, et al.  Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011;208:1949–62. References 101,103,104 illustrate the complex negative influence of peroxinitrite produced within tumor environment or tumor-draining lymph nodes by either myeloid or transformed cells on T cells.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3182051</ArticleId>
            <ArticleId IdType="pubmed">21930770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raes G, et al.  Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol. 2005;174:6561. author reply 6561–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15905489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lechner MG, Liebertz DJ, Epstein AL. Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells. J Immunol. 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2923483</ArticleId>
            <ArticleId IdType="pubmed">20644162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Pan PY, Gu P, Xu D, Chen SH. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res. 2004;64:1130–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14871848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narita Y, Wakita D, Ohkur T, Chamoto K, Nishimura T. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed Res. 2009;30:7–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19265258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev S, Gabrilovich D. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15814715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corzo CA, et al.  HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207:2439–53. This study demonstrated that MDSC in tumor microenvironment rapidly differentiate into TAMs and that this effect is mediated by hypoxia.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2964584</ArticleId>
            <ArticleId IdType="pubmed">20876310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doedens AL, et al.  Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010;70:7465–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2948598</ArticleId>
            <ArticleId IdType="pubmed">20841473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70:68–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2805057</ArticleId>
            <ArticleId IdType="pubmed">20028852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61:4756–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11406548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzoni A, et al.  Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002;168:689–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11777962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol. 2009;183:937–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2800824</ArticleId>
            <ArticleId IdType="pubmed">19553533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molon B, et al.  Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3182051</ArticleId>
            <ArticleId IdType="pubmed">21930770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32:345–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3164311</ArticleId>
            <ArticleId IdType="pubmed">21697013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182:240–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19109155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoechst B, et al.  Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50:799–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6357774</ArticleId>
            <ArticleId IdType="pubmed">19551844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkabets M, et al.  IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40:3347–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3373225</ArticleId>
            <ArticleId IdType="pubmed">21110318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan PY, et al.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010;70:99–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2805053</ArticleId>
            <ArticleId IdType="pubmed">19996287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang B, et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66:1123–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16424049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68:5439–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2887390</ArticleId>
            <ArticleId IdType="pubmed">18593947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011;117:6532–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21493801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe S, et al.  Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol. 2008;181:3291–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18714001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallina G, et al.  Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116:2777–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1578632</ArticleId>
            <ArticleId IdType="pubmed">17016559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, et al.  Antigen-specific CD4+ T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4062074</ArticleId>
            <ArticleId IdType="pubmed">22237629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, et al.  Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011;117:5381–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3109712</ArticleId>
            <ArticleId IdType="pubmed">21450901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179:977–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17617589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810498</ArticleId>
            <ArticleId IdType="pubmed">19342621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. JLleukocBiol. 2009;85:996–1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2698586</ArticleId>
            <ArticleId IdType="pubmed">19261929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2011;46:156–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20822377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marigo I, et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity. 2010;32:790–802. This manuscript shows that the transcription factor C/EBPβ, essential for the emergency granulopoiesis during inflammatory conditions, regulates the immunosuppressive activity of myeloid cells conditioned by growing tumors and provide the basis for molecular targeting of common tolerogenic pathways in myeloid cells.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20605485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, et al.  Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181:4666–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810501</ArticleId>
            <ArticleId IdType="pubmed">18802069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16365420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13:23–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2245859</ArticleId>
            <ArticleId IdType="pubmed">18167337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang B, et al.  CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007;252:86–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17257744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greifenberg V, Ribechini E, Rossner S, Lutz MB. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol. 2009;39:2865–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19637228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67:4507–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17483367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res. 2011;17:959–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3155407</ArticleId>
            <ArticleId IdType="pubmed">21224375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10:48–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14702634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng F, et al.  A critical role for Stat3 signaling in immune tolerance. Immunity. 2003;19:425–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14499117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nefedova Y, et al.  Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol. 2004;172:464–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14688356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nefedova Y, et al.  Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65:9525–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1351362</ArticleId>
            <ArticleId IdType="pubmed">16230418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70:4335–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20484028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4856025</ArticleId>
            <ArticleId IdType="pubmed">19851315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007;81:28–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16943388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng P, et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205:3325–2249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2556797</ArticleId>
            <ArticleId IdType="pubmed">18809714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farren MR, Carlson LM, Lee KP. Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunol Res. 2010;46:165–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19756409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, et al.  STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood. 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2953883</ArticleId>
            <ArticleId IdType="pubmed">20581311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sander LE, et al.  Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010;207:1453–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2901069</ArticleId>
            <ArticleId IdType="pubmed">20530204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15814715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movahedi K, et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood. 2008;111:4233–4244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18272812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements V, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174:636–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15634881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005;65:11743–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16357187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, et al.  IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003;170:270–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12496409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terabe M, et al.  Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003;198:1741–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2194133</ArticleId>
            <ArticleId IdType="pubmed">14657224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munera V, et al.  Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann Surg. 2010;251:120–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20032720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishii M, et al.  Epigenetic regulation of the alternatively activated macrophage phenotype. Blood. 2009;114:3244–54. This study demonstrates that M2 macrphage polarization is partially regulated epigenetically by chromatin/histone remodeling through an IL-4/STAT6-dependent mechanism.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2759649</ArticleId>
            <ArticleId IdType="pubmed">19567879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satoh T, et al.  The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 2010;11:936–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20729857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martino A, et al.  Mycobacterium bovis bacillus Calmette-Guerin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production. J Immunol. 2010;184:2038–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20083674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, et al.  Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol. 2010;176:2490–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2861113</ArticleId>
            <ArticleId IdType="pubmed">20348242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol. 2009;85:996–1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2698586</ArticleId>
            <ArticleId IdType="pubmed">19261929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, et al.  Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol. 2009;182:3801–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19265159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donkor MK, et al.  Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol. 2009;9:937–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19362167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J Leukoc Biol. 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20587738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez PC, et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202:931–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213169</ArticleId>
            <ArticleId IdType="pubmed">16186186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark CE, et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67:9518–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17909062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesina M, et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19:456–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21481788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda A, et al.  Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011;19:441–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3075548</ArticleId>
            <ArticleId IdType="pubmed">21481787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grivennikov S, et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2667107</ArticleId>
            <ArticleId IdType="pubmed">19185845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pufnock JS, Rothstein JL. Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol. 2009;182:5498–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19380798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borrello MG, et al.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A. 2005;102:14825–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1253545</ArticleId>
            <ArticleId IdType="pubmed">16203990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 2003;102:2138–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12750171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stairs DB, et al.  Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell. 2011;19:470–83. In the model of autochthonous cancer, release of soluble factors by tumor cells expanded and recruited immature myeloid cells, which possess immunosuppressive properties and promote desmoplasia by activating fibroblasts.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3077713</ArticleId>
            <ArticleId IdType="pubmed">21481789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Highfill SL, et al.  Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 2010;116:5738–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3031417</ArticleId>
            <ArticleId IdType="pubmed">20807889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Santo C, et al.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A. 2005;102:4185–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC554823</ArticleId>
            <ArticleId IdType="pubmed">15753302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, et al.  Anti-inflammatory triterpenoid blocks immune suppressive function of myeloid-derived suppressor cells and improves immune response in cancer. Clin Cancer Res. 2010;16:1812–1823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840181</ArticleId>
            <ArticleId IdType="pubmed">20215551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko JS, et al.  Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70:3526–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3426924</ArticleId>
            <ArticleId IdType="pubmed">20406969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko JS, et al.  Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15:2148–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19276286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozao-Choy J, et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69:2514–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4370269</ArticleId>
            <ArticleId IdType="pubmed">19276342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Cruijsen H, et al.  Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res. 2008;14:5884–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18794101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xin H, et al.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009;69:2506–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2664264</ArticleId>
            <ArticleId IdType="pubmed">19244102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veltman JD, et al.  COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10:464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2939552</ArticleId>
            <ArticleId IdType="pubmed">20804550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan PY, et al.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111:219–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2200807</ArticleId>
            <ArticleId IdType="pubmed">17885078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNardo D, et al.  Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery. 2011;1:54–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3203524</ArticleId>
            <ArticleId IdType="pubmed">22039576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67:11438–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2646404</ArticleId>
            <ArticleId IdType="pubmed">18056472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veltman JD, et al.  Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer. 2010;103:629–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2938257</ArticleId>
            <ArticleId IdType="pubmed">20664588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez A, et al.  Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol. 2011;186:264–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21135171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Priceman SJ, et al.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010;115:1461–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2826767</ArticleId>
            <ArticleId IdType="pubmed">20008303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fricke I, et al.  Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007;13:4840–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17699863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev S, et al.  Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181:346–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18566400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16166452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent J, et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20388795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Montero CM, et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3401888</ArticleId>
            <ArticleId IdType="pubmed">18446337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodumudi KN, et al.  A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16:4583–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3874864</ArticleId>
            <ArticleId IdType="pubmed">20702612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirza N, et al.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66:9299–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1586106</ArticleId>
            <ArticleId IdType="pubmed">16982775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusmartsev S, et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63:4441–4449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12907617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lathers D, Clark J, Achille N, Young M. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother. 2004;53:422–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14648070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol. 2007;178:1357–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17237382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65:3437–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15833879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerkar SP, et al.  IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3226001</ArticleId>
            <ArticleId IdType="pubmed">22056381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chmielewski M, Kopecky C, Hombach A, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that shut down tumor antigen expression. Cancer research. 2011 References 203 and 204 show that it is possible to reprogram tumor environment by adoptive transfer of T lymphocytes recognizing a tumor antigen and engineered to release IL-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21742772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss JM, et al.  Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med. 2010;207:2455–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2964582</ArticleId>
            <ArticleId IdType="pubmed">20921282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beatty GL, et al.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3406187</ArticleId>
            <ArticleId IdType="pubmed">21436454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rolny C, et al.  HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19:31–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21215706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagemann T, et al.  “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205:1261–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2413024</ArticleId>
            <ArticleId IdType="pubmed">18490490</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
